Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to eleven newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
Awards, effective July 6, 2026, include options for 34,700 shares at $9.66 and 11,375 RSUs with multi‑year vesting schedules.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market reaction after inducement grants announcement: OCUL -3.23% in the Jul 10 session
-3.23%
6 alerts
-3.23%Session close to close
-6.6%Trough in 26 hr 47 min
$2.26BMarket Cap
0.1xRel. Volume
In the Jul 10 session, OCUL declined 3.23%, reflecting a moderate negative market reaction.
Argus tracked a trough of -6.6% from its starting point during tracking.
Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
The company disclosed routine inducement equity awards totaling 34,700 options and 11,375 RSUs at a ...
Analysis
The company disclosed routine inducement equity awards totaling 34,700 options and 11,375 RSUs at a $9.66 exercise price for new hires, adding modest dilution alongside an already effective S-3 shelf and recent net insider selling that investors may monitor.
Key Figures
Inducement options granted:34,700 sharesInducement RSUs granted:11,375 sharesOption exercise price:$9.66 per share+5 more
8 metrics
Inducement options granted34,700 sharesAggregate non-statutory stock options for new non-executive hires
Inducement RSUs granted11,375 sharesAggregate restricted stock units for new non-executive hires
Option exercise price$9.66 per shareEqual to Nasdaq closing price on July 6, 2026 grant date
Option term10 yearsNon-statutory stock options granted July 6, 2026
Option vesting schedule4 years (25% after 1 year)Remainder vests monthly over following three years
RSU vesting schedule3 yearsEqual annual installments on first, second and third anniversaries
Participation in Clinical Trials at the Summit focused on OTX-TKI.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent OCUL headlines, including conferences and inducement grants, have produced mixed single-day price reactions without a consistent pattern.
Key Terms
nasdaq listing rule 5635(c)(4), non-statutory stock option, restricted stock unit, exercise price, +1 more
5 terms
nasdaq listing rule 5635(c)(4)regulatory
"under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
non-statutory stock optionfinancial
"consist of non-statutory stock option awards to purchase up to an aggregate of 34,700 shares"
A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.
restricted stock unitfinancial
"restricted stock unit awards representing the right to receive an aggregate of 11,375 shares"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
exercise pricefinancial
"The stock option awards have an exercise price of $9.66 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"vests over four years, with 25% of the original number of shares vesting on the one-year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive employees.The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted effective as of July 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 34,700 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 11,375 shares of Ocular’s common stock.The stock option awards have an exercise price of $9.66 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant.Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations bslattery@ocutx.com
FAQ
What inducement grants did Ocular Therapeutix (NASDAQ: OCUL) announce on July 9, 2026?
Ocular Therapeutix announced stock option and restricted stock unit inducement grants for eleven new non-executive employees. According to Ocular Therapeutix, the awards include 34,700 stock options and 11,375 RSUs granted under its 2019 Inducement Stock Incentive Plan.
How many Ocular Therapeutix OCUL shares are covered by the new inducement stock options?
The new inducement stock options cover up to 34,700 shares of Ocular Therapeutix common stock. According to Ocular Therapeutix, these non-statutory options were granted effective July 6, 2026, as part of its 2019 Inducement Stock Incentive Plan.
What is the exercise price and term of the new Ocular Therapeutix OCUL stock options?
The inducement stock options have an exercise price of $9.66 per share and a ten-year term. According to Ocular Therapeutix, $9.66 equals the July 6, 2026 Nasdaq Global Market closing price for its common stock.
How do the Ocular Therapeutix OCUL inducement stock options vest for new employees?
The inducement stock options vest over four years, starting with 25% after one year. According to Ocular Therapeutix, the remaining 75% vests in equal monthly installments over the following three years, subject to continued service.
What are the vesting terms for the Ocular Therapeutix OCUL restricted stock unit inducement awards?
The restricted stock unit awards vest in three equal annual installments over three years. According to Ocular Therapeutix, vesting occurs on the first, second, and third anniversaries of the grant date, contingent on the recipient’s continued service.
Under which plan were the July 2026 Ocular Therapeutix OCUL inducement awards granted?
The inducement awards were granted under the Ocular Therapeutix 2019 Inducement Stock Incentive Plan. According to Ocular Therapeutix, these grants comply with Nasdaq Listing Rule 5635(c)(4) and are governed by specific award agreements.
